Pfizer’s $14 billion deal to buy San Francisco’s Medivation Inc. adds a blockbuster prostate-cancer drug to the pharmaceutical giant’s roster of drugs and strengthens its line of lucrative cancer therapies. Medivation’s CEO, Dr. David Hung, described Pfizer as the “ideal partner” to extend the reach of its prostate cancer drug, called Xtandi, as well...